Fig. 2

Proportion of patients with ≥ 50% reduction from baseline in MMD across patient subgroups. CGRP, calcitonin gene-related peptide; CM, chronic migraine; EM, episodic migraine; GAD, generalized anxiety disorder; mAb, monoclonal antibody; MDD, major depressive disorder; MMD, monthly migraine days; MO, medication overuse. ^aNumber of patients with available assessment at each time point